Global News | Astellas

Month Year

May 13, 2013

Astellas Announces Cancellation of Treasury Stock

Tokyo, Japan, May 13, 2013 – Astellas Pharma Inc. (Tokyo: 4503; President and CEO: Yoshihiko Hatanaka, hereinafter called “the Company”) announced that at the meeting of the Board of...

Read more
May 13, 2013

Astellas Announces Issuance of Stock Acquisition Rights for Stock Option Scheme under Stock-Linked Compensation Plan

Read more
May 8, 2013

Astellas announces a3 (a-cube) selection results on public open innovation site, and start of international invitation for public participation in research

Tokyo, May 8, 2013 – Astellas Pharma Inc. (Astellas; Tokyo: 4503) today announced its selection results based on a3 (a-cube), a website (http://www.astellas.com/jp/a-cube/) launched on May 17,...

Read more
May 7, 2013

Astellas and Drais Partner To Develop Third Astellas Compound through Tacurion

InterWest Partners, Sutter Hill Ventures and Astellas Venture Management Invest $15 Million into Tacurion to Advance Compound

TOKYO, JAPAN and BRIDGEWATER, N.J., May 7, 2013 – Astellas Pharma Inc. (Tokyo: 4503, “Astellas”) and Drais Pharmaceuticals, Inc. (“Drais”) today announced that they have entered into a...

Read more
May 2, 2013

AVEO and Astellas Report FDA Oncologic Drug Advisory Committee Votes Tivozanib Application Did Not Demonstrate Favorable Benefit-to-Risk Evaluation in Treatment of Advanced Renal Cell Carcinoma

CAMBRIDGE, Mass. and TOKYO, Japan, May 2, 2013 - AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today reported that the U.S. Food and Drug Administration’s (FDA) Oncologic...

Read more
Apr 26, 2013

POSITIVE CHMP OPINION FOR XTANDITM (ENZALUTAMIDE) IN ADVANCED PROSTATE CANCER1

Enzalutamide recommended for approval in the European Union (EU) for the treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy 1

Chertsey, England and San Francisco, CA; 26 April, 2013: Today, Astellas Pharma Europe Ltd., the European Headquarters of Tokyo-based Astellas Pharma Inc. (TSE:4503), and Medivation, Inc. (Nasdaq:...

Read more
Apr 25, 2013

Astellas Announces Changes of Representative Directors, Directors and Corporate Auditors

Read more
Apr 15, 2013

New Hire Reinforces Global Compliance Structure

TOKYO, April 15, 2013 - Astellas Pharma Inc. (“Astellas”; Tokyo: 4503) today announced that Songlin Xue, M.D., Ph.D. has been named head of Global Pharmacovigilance (GPV). Dr. Xue will be...

Read more
Apr 10, 2013

Astellas and Johns Hopkins University researchers identify a novel action of quetiapine in the regulation of cell-cycle related p21/Cdkn1a gene expression in CD-1 mice ～Data Reported in U.S. Scientific Journal, Translational Psychiatry～

TOKYO, April 10, 2013 - Astellas Pharma Inc. (“Astellas”; Tokyo:4503) announced today that its collaborative research project with Johns HopkinsUniversity School of Medicine (“JHU”;...

Read more
Apr 4, 2013

Astellas and Ambrx Initiate Collaboration for Discovery and Development of Next-Generation Antibody Drug Conjugates for Oncology

TOKYO and SAN DIEGO, April 4, 2013 – Astellas Pharma Inc. (Tokyo: 4503, “Astellas”) today entered into a collaboration with Ambrx Inc. (“Ambrx”) for the discovery and development of...

Read more
Apr 1, 2013

Medivation and Astellas Provide Update on PREVAIL -Companies Announce Phase 3 PREVAIL Interim Analysis Expected to Occur in 2013-

San Francisco, CA and Tokyo, Japan – April 1, 2013 – Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. (TSE: 4503) today announced that the companies have established an updated interim...

Read more
Mar 25, 2013

Approval in Japan for Treating Functional Dyspepsia with Acofide®

Tokyo, March 25, 2013 - Zeria Pharmaceutical Co., Ltd. (Tokyo: 4559; “Zeria”) and Astellas Pharma Inc. (Tokyo: 4503; “Astellas”) announced today that as of March 25, Zeria has obtained the...

Read more
Mar 18, 2013

Notice of Completion of Acquisition of Own Shares (Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Tokyo, March 18, 2013 – Astellas Pharma Inc. (Headquarters: Tokyo, President and CEO: Yoshihiko Hatanaka, hereinafter called “the Company”) announced that it completed acquisition of its own...

Read more
Mar 13, 2013

Astellas Pharma Inc.: Submits Application for Marketing Approval of Ipragliflozin (ASP1941), SGLT2 Inhibitor for Treatment of Type 2 Diabetes, in Japan

Read more
Mar 12, 2013

Astellas and Ambit to End Collaboration for Joint Development and Commercialization of FLT3 Kinase Inhibitors

Read more
Mar 11, 2013

Non-inferiority Observed in Phase III Clinical Trial of Seasonal Flu Vaccine ASP7374

Read more
Mar 7, 2013

Astellas and UCB Launch Cimzia® (certolizumab pegol) in Japan for the treatment of adult patients with rheumatoid arthritis

Tokyo, Japan, 7 March, 2013 – Astellas Pharma Inc. (“Astellas”;Tokyo:4503; President and CEO: Yoshihiko Hatanaka) and UCB Japan (“UCB Japan”: Tokyo, Japan, President and Representative...

Read more
Feb 28, 2013

Astellas Voluntarily Adopts International Financial Reporting Standards (IFRS)

Read more
Feb 26, 2013

NEW CLASS OF TREATMENT NOW AVAILABLE FOR PATIENTS WITH OVERACTIVE BLADDER

Read more
Feb 21, 2013

Pasetocin® and Sawacillin® : Approval for Additional Indication for Helicobacter pylori Eradication by Triple Therapy with Proton Pump Inhibitors and either Clarithromycin or Metronidazole

Read more
Feb 20, 2013

Astellas Submits Additional Indication Application for Hypnosedative, Dormicum® in Japan

Read more
Feb 13, 2013

Enzalutamide Data Presented at ASCO GU Symposium

-- Six Abstracts Presented Include Data from Phase II Study Investigating XTANDI® (enzalutamide) Capsules in Hormone-Naïve Prostate Cancer --

Read more
Feb 12, 2013

AVEO and Astellas Report Final Overall Survival Results from TIVO-1

- Median Overall Survival of 28.8 Months Reported for Tivozanib in Patients with Advanced Kidney Cancer -

CAMBRIDGE, Mass. and TOKYO, Japan, February 12, 2013 - AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced overall survival (OS) for tivozanib, an investigational...

Read more
Feb 5, 2013

Astellas Pharma Inc.: Reorganization of Astellas’ Global Management Structure

Read more
Feb 1, 2013

Astellas Announces Relocation of Global HQ building in Tokyo

Read more
Feb 1, 2013

Astellas Announces Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Read more
Jan 30, 2013

Enzalutamide Data to Be Presented at ASCO GU Symposium

Read more
Jan 29, 2013

AVEO and Astellas Announce Presentations of Tivozanib Clinical Data at 2013 ASCO Genitourinary Cancers Symposium

Read more
Jan 16, 2013

FDA ACCEPTS SUPPLEMENTAL NEW DRUG APPLICATION FOR TARCEVA® (ERLOTINIB) TABLETS FOR GENETICALLY DISTINCT FORM OF ADVANCED LUNG CANCER

– The Tarceva application has been granted priority review –

Read more
Jan 11, 2013

NEW CLASS OF TREATMENT FOR OVERACTIVE BLADDER APPROVED IN EUROPE

Astellas Pharma Europe Ltd., Chertsey, UK, 11th January 2013. A new treatment, BETMIGATM (mirabegron) has received approval from the European Commission (EC) for the treatment of overactive...

Read more
Jan 10, 2013

Astellas and Sanwa Launch “ARGAMATE® 89.29% Granule 5.6g” - Hyperkalemia Treatment

Read more
Dec 25, 2012

Astellas and UCB announce approval of Cimzia®(certolizumab pegol) in Japan for the treatment of adult patients with rheumatoid arthritis

Tokyo, Japan and Brussels, Belgium, 25th December, 2012 – Astellas Pharma Inc. (“Astellas”;Tokyo:4503; President and CEO: Yoshihiko Hatanaka) and UCB S.A. (“UCB"; Brussels, Belgium, CEO:...

Read more
Dec 21, 2012

Approval for Manufacturing and Marketing of "Micamlo® Combination Tablets BP," an Antihypertensive Drug

- The first combination drug of a high-dose ARB and a long acting CCB with a powerful antihypertensive effect lasting for 24 hours in Japan -

Tokyo, Japan, December 21, 2012 – Nippon Boehringer Ingelheim Co., Ltd. (Headquarters: Shinagawa-ku, Tokyo; President: Yoshiaki Aono; hereinafter “NBI”) and Astellas Pharma Inc. (Tokyo:4503,...

Read more
Dec 14, 2012

Astellas announces recruitment completion of phase 3 pivotal study of isavuconazole, an agent for the potential primary treatment of invasive and life-threatening fungal infections

Read more
Dec 12, 2012

FibroGen and Astellas Announce Initiation of Phase 3 Trial of FG-4592/ASP1517 for Treatment of Anemia of Chronic Kidney Disease

Read more
Dec 12, 2012

Beyond Patent Cliff, Towards New Beyond Patent Cliff, Towards Towards New Growth Stage with Innovative Drugs

Read more
Dec 11, 2012

Astellas and UMN announce Completion of Administration of Phase III Clinical Trials of Seasonal Flu Vaccine ASP7374

Read more
Dec 11, 2012

Notice of Completion of Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Read more
Dec 10, 2012

Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology

Highest level of single agent activity observed to date for FLT3-targeted therapy in relapsed/refractory AML

Read more
Dec 4, 2012

AVEO and Astellas Announce Initiation of Patient Enrollment in Phase 2 Trial of Tivozanib in Combination with Paclitaxel in Patients with Advanced Triple Negative Breast Cancer

BATON-BC Trial Initiation Marks Entry into Third Tumor Type for Tivozanib Clinical Development Progra

CAMBRIDGE, Mass. and TOKYO, Japan, December 3, 2012 - AVEO Oncology (NASDAQ:AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced the initiation of patient enrollment in a randomized,...

Read more
Dec 4, 2012

Astellas Announces Acceptance of U.S. New Drug Application for Tacrolimus Extended Release Capsule

Read more
Nov 28, 2012

AVEO and Astellas Announce FDA Acceptance of NDA Filing for Tivozanib for the Treatment of Advanced Renal Cell Carcinoma

CAMBRIDGE, Mass. and TOKYO, Japan, November 28, 2012 -- AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced that the U.S. Food and Drug Administration (FDA) has...

Read more
Nov 20, 2012

Astellas Submits Supplemental New Drug Application to FDA for Tarceva® as a First-Line Therapy in Genetically Distinct Form of Non-Small Cell Lung Cancer

Read more
Nov 15, 2012

Astellas received the Notice from AstraZeneca Not to Exercise the Option to Acquire Diabetes Assets from Prosidion, a Subsidiary of Astellas

Tokyo, 15 November, 2012 –Astellas Pharma Inc. (Tokyo: 4503, ”Astellas”) announced today that it received a notice from AstraZeneca not to exercise an exclusive option to acquire the Phase...

Read more
Nov 6, 2012

Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting

Read more
Nov 1, 2012

Astellas Announces Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Read more
Oct 30, 2012

Astellas Pharma Announces Launch of Quattrovac® for Subcutaneous Injection Syringe, Adsorbed Purified Pertussis Diptheria Tetanus Inactivated Poliomyelitis (Sabin strain) Combined Vaccine

Read more
Oct 22, 2012

Astellas Enters Collaborative New Drug Discovery Research with AIST for Neglected Tropical Diseases Caused by Protozoan Parasites

- Through Drug Design Using Fragment Evolution -

Read more
Oct 22, 2012

Astellas Launches Gonax® (Degarelix Acetate) for Subcutaneous Injection in Japan for Treating Prostate Cancer

Read more
Oct 22, 2012

MYRBETRIQ™ (mirabegron), Overactive Bladder Treatment from Astellas, Now Available Through U.S. Pharmacies

Read more

Show per page

Choose Language

News